KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances: 2014-2021

Historic Long-Term Debt Issuances for Vertex Pharmaceuticals (VRTX) over the last 3 years, with Dec 2021 value amounting to $10.0 million.

  • Vertex Pharmaceuticals' Long-Term Debt Issuances rose 114.68% to $10.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $22.6 million, marking a year-over-year increase of 1.35%. This contributed to the annual value of $22.6 million for FY2021, which is 69.92% up from last year.
  • Vertex Pharmaceuticals' Long-Term Debt Issuances amounted to $10.0 million in Q4 2021, which was up 900.00% from $1.0 million recorded in Q3 2021.
  • In the past 5 years, Vertex Pharmaceuticals' Long-Term Debt Issuances registered a high of $30.0 million during Q4 2017, and its lowest value of $1.0 million during Q3 2021.
  • Moreover, its 3-year median value for Long-Term Debt Issuances was $4.7 million (2020), whereas its average is $5.1 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Long-Term Debt Issuances soared by 131.53% in 2017, and later plummeted by 73.78% in 2018.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Long-Term Debt Issuances stood at $30.0 million in 2017, then slumped by 73.78% to $7.9 million in 2018, then climbed by 14.52% to $9.0 million in 2019, then tumbled by 48.23% to $4.7 million in 2020, then spiked by 114.68% to $10.0 million in 2021.
  • Its Long-Term Debt Issuances stands at $10.0 million for Q4 2021, versus $1.0 million for Q3 2021 and $8.0 million for Q2 2021.